Across TCGA pan-cancer cohorts, TEAD4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TEAD4 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TEAD4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TEAD4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, LIHC, and UCEC are the cancer types where TEAD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.151	0.684	<.001	35	view →
LIHC	DFS	Median	All	0.120	0.544	.011	12	view →
UCEC	DFS	Median	All	0.955	0.612	.017	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TEAD4 tumor-vs-normal RNA expression · all TEAD4 data types